Munich Startup

News & Podcast

Stay up to date with the latest stories, deep-dives and interviews from the Munich startup ecosystem. From funding deals to founder portraits and tech trends.

Format:
Category:
4 Results– filtered by:#Meliodays Medical
Women in Tech: Simone Sabbione from Meliodays Medical
Interviews

Women in Tech: Simone Sabbione from Meliodays Medical

“If men menstruated, there would already be a solution.” This sentence wouldn’t let Simone Sabbione go and became the spark for her first founding. In 2022, the healthtech startup Meliodays Medical was created. Together with her team, consisting of her husband Martin Sabbione and her brother and gynecologist Dr. Benjamin Wolf, the business graduate developed MelioOne: a hormone-free, locally effective therapy for menstrual pain. In an interview, the CEO of Meliodays Medical talks about what she knows today about founding and when the right time is to do it—and what she would ask Elon Musk. First published on: April 14, 2025

Saskia Doll
S. Doll
22.12.25
2 Min.
Meliodays Medical and Celanese develop hormone-free IUD against menstrual pain
Deals

Meliodays Medical and Celanese develop hormone-free IUD against menstrual pain

The Munich medtech startup Meliodays Medical is cooperating with Celanese in the development of MelioOne – a hormone-free IUD for localized relief of menstrual pain.

Regina Bruckschlögl
R. Bruckschlögl
05.08.25
3 Min.
Meliodays Medical: Hormone-free treatment for period pain
Interviews

Meliodays Medical: Hormone-free treatment for period pain

A hormone-free IUD for period pain – doesn’t exist yet? Well, it will soon! Meliodays Medical is developing MelioOne, an innovative, locally-acting alternative to conventional painkillers. Simone Sabbione, CEO and co-founder, talks about how the idea came about and where the startup wants to be in five years.

Saskia Doll
S. Doll
07.04.25
2 Min.
Meliodays Medical secures 800,000 euros in pre-seed financing
Deals

Meliodays Medical secures 800,000 euros in pre-seed financing

Meliodays Medical has successfully completed an oversubscribed pre-seed financing round and receives over 800,000 euros. The capital is to be invested in the development of an innovative therapy for menstrual pain.

Regina Bruckschlögl
R. Bruckschlögl
20.03.25
2 Min.